West Pharmaceutical said its 2025 Annual Meeting of Shareholders was held virtually on May 6, 2025. Shareholders holding 65,014,244 of the 72,292,731 common shares outstanding as of February 28, 2025, the record date, were present virtually or represented by proxy, or 89.93%.

1. 01

   West Pharmaceutical said its 2025 Annual Meeting of Shareholders was held virtually on May 6, 2025. Shareholders holding 65,014,244 of the 72,292,731 common shares outstanding as of February 28, 2025, the record date, were present virtually or represented by proxy, or 89.93%.

2. 02

   The company said shareholders approved an amendment and restatement of its Articles of Incorporation to add a right for shareholders to call a special meeting, with 62,707,017 votes for, 88,400 against and 65,263 abstentions.

3. 03

   The company said shareholders approved, on an advisory basis, the compensation of its named executive officers with 59,222,338 votes for and 3,516,476 against. It said shareholders approved the amendment and restatement of its 2016 Omnibus Incentive Compensation Plan with 60,862,053 votes for and 1,883,395 against. Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm received 60,537,221 votes for.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.